The BioCommerce Week Index gained 10.6 percent for the year 2006, adjusting for additions and deletions in the Index during the year. The Index beat the Nasdaq and Nasdaq Biotech Index, which gained 9.5 percent and 1.0 percent, respectively, for the year. However, the BCW Index could not keep pace with the Dow Jones Industrial Average, which climbed 16.3 percent for the year as it hit historical highs in December.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.